nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—ABCG2—Dactinomycin—ocular cancer	0.11	0.492	CbGbCtD
Dasatinib—ABCG2—Carboplatin—ocular cancer	0.0742	0.331	CbGbCtD
Dasatinib—ABCB1—Dactinomycin—ocular cancer	0.0398	0.177	CbGbCtD
Dasatinib—WEE2—lymphoid tissue—ocular cancer	0.00691	0.0412	CbGeAlD
Dasatinib—EPHB1—eye—ocular cancer	0.00583	0.0348	CbGeAlD
Dasatinib—EPHB1—retina—ocular cancer	0.00578	0.0345	CbGeAlD
Dasatinib—TEC—lymphoid tissue—ocular cancer	0.00524	0.0312	CbGeAlD
Dasatinib—EPHB2—retina—ocular cancer	0.00475	0.0283	CbGeAlD
Dasatinib—EPHA8—eye—ocular cancer	0.00459	0.0274	CbGeAlD
Dasatinib—BMX—epithelium—ocular cancer	0.00448	0.0267	CbGeAlD
Dasatinib—EPHA3—eye—ocular cancer	0.00401	0.0239	CbGeAlD
Dasatinib—EPHA3—retina—ocular cancer	0.00398	0.0237	CbGeAlD
Dasatinib—STAT5B—epithelium—ocular cancer	0.00397	0.0237	CbGeAlD
Dasatinib—ZAK—eye—ocular cancer	0.00363	0.0216	CbGeAlD
Dasatinib—EPHA5—eye—ocular cancer	0.00355	0.0212	CbGeAlD
Dasatinib—FRK—lymphoid tissue—ocular cancer	0.00354	0.0211	CbGeAlD
Dasatinib—EPHA5—retina—ocular cancer	0.00352	0.021	CbGeAlD
Dasatinib—BLK—lymphoid tissue—ocular cancer	0.00341	0.0203	CbGeAlD
Dasatinib—EPHB2—lymphoid tissue—ocular cancer	0.00337	0.0201	CbGeAlD
Dasatinib—TXK—lymphoid tissue—ocular cancer	0.00327	0.0195	CbGeAlD
Dasatinib—TESK1—eye—ocular cancer	0.00321	0.0191	CbGeAlD
Dasatinib—BMPR1B—epithelium—ocular cancer	0.00318	0.019	CbGeAlD
Dasatinib—STAT5B—lymphoid tissue—ocular cancer	0.00306	0.0182	CbGeAlD
Dasatinib—CSK—eye—ocular cancer	0.00294	0.0175	CbGeAlD
Dasatinib—RIPK2—eye—ocular cancer	0.00273	0.0163	CbGeAlD
Dasatinib—RIPK2—retina—ocular cancer	0.0027	0.0161	CbGeAlD
Dasatinib—ZAK—lymphoid tissue—ocular cancer	0.00256	0.0152	CbGeAlD
Dasatinib—RIPK2—epithelium—ocular cancer	0.0025	0.0149	CbGeAlD
Dasatinib—LYN—lymphoid tissue—ocular cancer	0.00249	0.0148	CbGeAlD
Dasatinib—BTK—lymphoid tissue—ocular cancer	0.00244	0.0145	CbGeAlD
Dasatinib—ERBB3—epithelium—ocular cancer	0.00239	0.0142	CbGeAlD
Dasatinib—FMO3—eye—ocular cancer	0.00234	0.0139	CbGeAlD
Dasatinib—MAPK14—epithelium—ocular cancer	0.00222	0.0133	CbGeAlD
Dasatinib—LIMK2—lymphoid tissue—ocular cancer	0.00215	0.0128	CbGeAlD
Dasatinib—EPHB4—epithelium—ocular cancer	0.00211	0.0126	CbGeAlD
Dasatinib—JAK2—epithelium—ocular cancer	0.00209	0.0125	CbGeAlD
Dasatinib—CSK—lymphoid tissue—ocular cancer	0.00207	0.0123	CbGeAlD
Dasatinib—EPHA2—epithelium—ocular cancer	0.00207	0.0123	CbGeAlD
Dasatinib—HCK—lymphoid tissue—ocular cancer	0.00204	0.0122	CbGeAlD
Dasatinib—YES1—eye—ocular cancer	0.00204	0.0121	CbGeAlD
Dasatinib—YES1—retina—ocular cancer	0.00202	0.012	CbGeAlD
Dasatinib—SRC—eye—ocular cancer	0.00196	0.0117	CbGeAlD
Dasatinib—SRC—retina—ocular cancer	0.00194	0.0116	CbGeAlD
Dasatinib—SIK1—lymphoid tissue—ocular cancer	0.00188	0.0112	CbGeAlD
Dasatinib—ERBB3—lymphoid tissue—ocular cancer	0.00184	0.011	CbGeAlD
Dasatinib—MAP3K2—lymphoid tissue—ocular cancer	0.00182	0.0109	CbGeAlD
Dasatinib—SRC—epithelium—ocular cancer	0.00179	0.0107	CbGeAlD
Dasatinib—CSF1R—eye—ocular cancer	0.00176	0.0105	CbGeAlD
Dasatinib—MAPK14—lymphoid tissue—ocular cancer	0.00171	0.0102	CbGeAlD
Dasatinib—FGR—lymphoid tissue—ocular cancer	0.00171	0.0102	CbGeAlD
Dasatinib—JAK2—lymphoid tissue—ocular cancer	0.00161	0.00961	CbGeAlD
Dasatinib—EPHA2—lymphoid tissue—ocular cancer	0.00159	0.0095	CbGeAlD
Dasatinib—FYN—lymphoid tissue—ocular cancer	0.00159	0.00948	CbGeAlD
Dasatinib—PDGFRB—eye—ocular cancer	0.00156	0.0093	CbGeAlD
Dasatinib—MAP4K5—lymphoid tissue—ocular cancer	0.00155	0.00927	CbGeAlD
Dasatinib—KIT—epithelium—ocular cancer	0.00146	0.00871	CbGeAlD
Dasatinib—YES1—lymphoid tissue—ocular cancer	0.00144	0.00856	CbGeAlD
Dasatinib—PDGFRB—epithelium—ocular cancer	0.00143	0.00851	CbGeAlD
Dasatinib—PDGFRA—lymphoid tissue—ocular cancer	0.00141	0.00839	CbGeAlD
Dasatinib—ABL1—eye—ocular cancer	0.00139	0.00829	CbGeAlD
Dasatinib—SRC—lymphoid tissue—ocular cancer	0.00138	0.00823	CbGeAlD
Dasatinib—ABL1—retina—ocular cancer	0.00138	0.00822	CbGeAlD
Dasatinib—CSF1R—lymphoid tissue—ocular cancer	0.00124	0.00739	CbGeAlD
Dasatinib—CYP1B1—eye—ocular cancer	0.00118	0.00702	CbGeAlD
Dasatinib—KIT—lymphoid tissue—ocular cancer	0.00113	0.00671	CbGeAlD
Dasatinib—PDGFRB—lymphoid tissue—ocular cancer	0.0011	0.00655	CbGeAlD
Dasatinib—ABL1—lymphoid tissue—ocular cancer	0.00098	0.00584	CbGeAlD
Dasatinib—CYP1B1—lymphoid tissue—ocular cancer	0.00083	0.00495	CbGeAlD
Dasatinib—CYP1A1—epithelium—ocular cancer	0.000762	0.00454	CbGeAlD
Dasatinib—ABCB1—retina—ocular cancer	0.000429	0.00256	CbGeAlD
Dasatinib—ABCB1—epithelium—ocular cancer	0.000396	0.00236	CbGeAlD
Dasatinib—ABCB1—lymphoid tissue—ocular cancer	0.000305	0.00182	CbGeAlD
Dasatinib—PDGFRB—Immune System—EP300—ocular cancer	1.17e-05	1.93e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—AKT1—ocular cancer	1.17e-05	1.93e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—AKT1—ocular cancer	1.16e-05	1.91e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—AKT1—ocular cancer	1.15e-05	1.9e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—EP300—ocular cancer	1.15e-05	1.89e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—AKT1—ocular cancer	1.15e-05	1.88e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CDKN1A—ocular cancer	1.15e-05	1.88e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—EP300—ocular cancer	1.14e-05	1.88e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GNA11—ocular cancer	1.14e-05	1.88e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—CDKN1A—ocular cancer	1.14e-05	1.87e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—ocular cancer	1.14e-05	1.87e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—EP300—ocular cancer	1.14e-05	1.87e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CDKN1B—ocular cancer	1.14e-05	1.87e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—EP300—ocular cancer	1.13e-05	1.86e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—CDKN1B—ocular cancer	1.13e-05	1.86e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—AKT1—ocular cancer	1.13e-05	1.86e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CDKN1A—ocular cancer	1.13e-05	1.86e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—AKT1—ocular cancer	1.13e-05	1.86e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—MYC—ocular cancer	1.12e-05	1.85e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TGFB1—ocular cancer	1.12e-05	1.84e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—AKT1—ocular cancer	1.12e-05	1.84e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—E2F1—ocular cancer	1.11e-05	1.83e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MDM2—ocular cancer	1.11e-05	1.83e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—HRAS—ocular cancer	1.11e-05	1.83e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—HRAS—ocular cancer	1.11e-05	1.83e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—MYC—ocular cancer	1.11e-05	1.82e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—HRAS—ocular cancer	1.11e-05	1.82e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—TGFB1—ocular cancer	1.11e-05	1.82e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—CDKN1A—ocular cancer	1.1e-05	1.81e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—EP300—ocular cancer	1.09e-05	1.79e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—HRAS—ocular cancer	1.09e-05	1.79e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—AKT1—ocular cancer	1.09e-05	1.79e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—MDM2—ocular cancer	1.09e-05	1.79e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—EP300—ocular cancer	1.08e-05	1.78e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CCND1—ocular cancer	1.08e-05	1.78e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—AKT1—ocular cancer	1.08e-05	1.77e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EP300—ocular cancer	1.08e-05	1.77e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CDKN1B—ocular cancer	1.07e-05	1.77e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—ocular cancer	1.07e-05	1.77e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—HRAS—ocular cancer	1.06e-05	1.75e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GNAQ—ocular cancer	1.06e-05	1.75e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—AKT1—ocular cancer	1.06e-05	1.75e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—HRAS—ocular cancer	1.06e-05	1.74e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MDM2—ocular cancer	1.05e-05	1.73e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—MYC—ocular cancer	1.05e-05	1.73e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CDKN1A—ocular cancer	1.05e-05	1.72e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—TGFB1—ocular cancer	1.05e-05	1.72e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—EP300—ocular cancer	1.05e-05	1.72e-05	CbGpPWpGaD
Dasatinib—FMO3—Metabolism—AKT1—ocular cancer	1.04e-05	1.72e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—CDKN1A—ocular cancer	1.04e-05	1.72e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—AKT1—ocular cancer	1.04e-05	1.72e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—MDM2—ocular cancer	1.04e-05	1.71e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MYC—ocular cancer	1.03e-05	1.69e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TGFB1—ocular cancer	1.02e-05	1.69e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CDKN1B—ocular cancer	1.01e-05	1.67e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EP300—ocular cancer	9.97e-06	1.64e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—EP300—ocular cancer	9.93e-06	1.63e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—CDKN1B—ocular cancer	9.91e-06	1.63e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CDKN1A—ocular cancer	9.9e-06	1.63e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MYC—ocular cancer	9.9e-06	1.63e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TGFB1—ocular cancer	9.87e-06	1.62e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—HRAS—ocular cancer	9.8e-06	1.61e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—AKT1—ocular cancer	9.8e-06	1.61e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—AKT1—ocular cancer	9.8e-06	1.61e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—AKT1—ocular cancer	9.78e-06	1.61e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CCND1—ocular cancer	9.67e-06	1.59e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—AKT1—ocular cancer	9.61e-06	1.58e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—MDM2—ocular cancer	9.61e-06	1.58e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CDKN1B—ocular cancer	9.6e-06	1.58e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CDKN1B—ocular cancer	9.5e-06	1.56e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MDM2—ocular cancer	9.47e-06	1.56e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—MYC—ocular cancer	9.45e-06	1.55e-05	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—MYC—ocular cancer	9.44e-06	1.55e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—TGFB1—ocular cancer	9.42e-06	1.55e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—HRAS—ocular cancer	9.42e-06	1.55e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—EP300—ocular cancer	9.42e-06	1.55e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—HRAS—ocular cancer	9.41e-06	1.55e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—AKT1—ocular cancer	9.39e-06	1.54e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CDKN1A—ocular cancer	9.36e-06	1.54e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—AKT1—ocular cancer	9.32e-06	1.53e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MDM2—ocular cancer	9.27e-06	1.53e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—ocular cancer	9.22e-06	1.52e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CCND1—ocular cancer	9.16e-06	1.51e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—CDKN1A—ocular cancer	9.14e-06	1.5e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MDM2—ocular cancer	9.13e-06	1.5e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GNA11—ocular cancer	9.12e-06	1.5e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—MYC—ocular cancer	9.11e-06	1.5e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—TGFB1—ocular cancer	9.08e-06	1.49e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—HRAS—ocular cancer	8.92e-06	1.47e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EP300—ocular cancer	8.9e-06	1.46e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CDKN1A—ocular cancer	8.86e-06	1.46e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—HRAS—ocular cancer	8.82e-06	1.45e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MDM2—ocular cancer	8.79e-06	1.45e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CDKN1B—ocular cancer	8.77e-06	1.44e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CDKN1A—ocular cancer	8.77e-06	1.44e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—HRAS—ocular cancer	8.7e-06	1.43e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—EP300—ocular cancer	8.7e-06	1.43e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MYC—ocular cancer	8.69e-06	1.43e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MDM2—ocular cancer	8.68e-06	1.43e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TGFB1—ocular cancer	8.67e-06	1.43e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—MYC—ocular cancer	8.66e-06	1.42e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—AKT1—ocular cancer	8.66e-06	1.42e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CDKN1B—ocular cancer	8.65e-06	1.42e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—TGFB1—ocular cancer	8.64e-06	1.42e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GNAQ—ocular cancer	8.48e-06	1.39e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CDKN1B—ocular cancer	8.47e-06	1.39e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—ocular cancer	8.43e-06	1.39e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EP300—ocular cancer	8.43e-06	1.39e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—EP300—ocular cancer	8.34e-06	1.37e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CDKN1B—ocular cancer	8.33e-06	1.37e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—AKT1—ocular cancer	8.32e-06	1.37e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—AKT1—ocular cancer	8.31e-06	1.37e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CCND1—ocular cancer	8.25e-06	1.36e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—HRAS—ocular cancer	8.24e-06	1.36e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—ocular cancer	8.13e-06	1.34e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CDKN1A—ocular cancer	8.1e-06	1.33e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCND1—ocular cancer	8.08e-06	1.33e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—HRAS—ocular cancer	8.06e-06	1.33e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—HRAS—ocular cancer	8.06e-06	1.33e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—HRAS—ocular cancer	8.04e-06	1.32e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CDKN1B—ocular cancer	8.02e-06	1.32e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CDKN1A—ocular cancer	7.98e-06	1.31e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCND1—ocular cancer	7.95e-06	1.31e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CDKN1B—ocular cancer	7.92e-06	1.3e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—AKT1—ocular cancer	7.88e-06	1.3e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—HRAS—ocular cancer	7.87e-06	1.29e-05	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—AKT1—ocular cancer	7.84e-06	1.29e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HRAS—ocular cancer	7.83e-06	1.29e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CDKN1A—ocular cancer	7.81e-06	1.29e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—AKT1—ocular cancer	7.78e-06	1.28e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HRAS—ocular cancer	7.77e-06	1.28e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—EP300—ocular cancer	7.76e-06	1.28e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MYC—ocular cancer	7.76e-06	1.28e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—HRAS—ocular cancer	7.75e-06	1.27e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TGFB1—ocular cancer	7.74e-06	1.27e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—EP300—ocular cancer	7.7e-06	1.27e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CDKN1A—ocular cancer	7.69e-06	1.27e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—AKT1—ocular cancer	7.68e-06	1.26e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCND1—ocular cancer	7.66e-06	1.26e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MDM2—ocular cancer	7.6e-06	1.25e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EP300—ocular cancer	7.59e-06	1.25e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—MYC—ocular cancer	7.58e-06	1.25e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—TGFB1—ocular cancer	7.56e-06	1.24e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—ocular cancer	7.56e-06	1.24e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—ocular cancer	7.46e-06	1.23e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EP300—ocular cancer	7.43e-06	1.22e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—ocular cancer	7.42e-06	1.22e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CDKN1A—ocular cancer	7.41e-06	1.22e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—ocular cancer	7.36e-06	1.21e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—ocular cancer	7.34e-06	1.21e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TGFB1—ocular cancer	7.33e-06	1.21e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EP300—ocular cancer	7.32e-06	1.2e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CDKN1A—ocular cancer	7.31e-06	1.2e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—ocular cancer	7.27e-06	1.2e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—ocular cancer	7.15e-06	1.18e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—ocular cancer	7.13e-06	1.17e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—ocular cancer	7.12e-06	1.17e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—ocular cancer	7.12e-06	1.17e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—ocular cancer	7.1e-06	1.17e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—EP300—ocular cancer	7.06e-06	1.16e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EP300—ocular cancer	7.05e-06	1.16e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GNA11—ocular cancer	7.04e-06	1.16e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EP300—ocular cancer	6.96e-06	1.14e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—ocular cancer	6.95e-06	1.14e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1B—ocular cancer	6.94e-06	1.14e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—ocular cancer	6.92e-06	1.14e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—ocular cancer	6.86e-06	1.13e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—ocular cancer	6.84e-06	1.13e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—ocular cancer	6.84e-06	1.13e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—ocular cancer	6.82e-06	1.12e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—ocular cancer	6.8e-06	1.12e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MDM2—ocular cancer	6.73e-06	1.11e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—ocular cancer	6.71e-06	1.1e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—TGFB1—ocular cancer	6.7e-06	1.1e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—ocular cancer	6.62e-06	1.09e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—ocular cancer	6.62e-06	1.09e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TGFB1—ocular cancer	6.6e-06	1.09e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—ocular cancer	6.59e-06	1.08e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—ocular cancer	6.55e-06	1.08e-05	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—ocular cancer	6.55e-06	1.08e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GNAQ—ocular cancer	6.54e-06	1.08e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—ocular cancer	6.5e-06	1.07e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—ocular cancer	6.48e-06	1.07e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TGFB1—ocular cancer	6.46e-06	1.06e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—ocular cancer	6.45e-06	1.06e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1A—ocular cancer	6.4e-06	1.05e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—ocular cancer	6.38e-06	1.05e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—ocular cancer	6.37e-06	1.05e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TGFB1—ocular cancer	6.36e-06	1.05e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—ocular cancer	6.32e-06	1.04e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1B—ocular cancer	6.14e-06	1.01e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—ocular cancer	6.14e-06	1.01e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TGFB1—ocular cancer	6.13e-06	1.01e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—ocular cancer	6.09e-06	1e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EP300—ocular cancer	6.09e-06	1e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—ocular cancer	6.06e-06	9.97e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TGFB1—ocular cancer	6.05e-06	9.95e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—ocular cancer	6.03e-06	9.92e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—ocular cancer	6.02e-06	9.91e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—ocular cancer	6e-06	9.88e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—ocular cancer	5.95e-06	9.8e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—ocular cancer	5.86e-06	9.64e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—ocular cancer	5.77e-06	9.49e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—ocular cancer	5.71e-06	9.4e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—ocular cancer	5.69e-06	9.37e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1A—ocular cancer	5.67e-06	9.33e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—ocular cancer	5.43e-06	8.94e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EP300—ocular cancer	5.39e-06	8.88e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—ocular cancer	5.38e-06	8.85e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—ocular cancer	5.32e-06	8.75e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—ocular cancer	5.31e-06	8.74e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TGFB1—ocular cancer	5.3e-06	8.72e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—ocular cancer	5.27e-06	8.67e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—ocular cancer	5.26e-06	8.65e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—ocular cancer	5.24e-06	8.62e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—ocular cancer	5.2e-06	8.55e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—ocular cancer	5.09e-06	8.38e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—ocular cancer	5.09e-06	8.37e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—EP300—ocular cancer	5.06e-06	8.32e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—ocular cancer	5.04e-06	8.3e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—ocular cancer	5.04e-06	8.3e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—ocular cancer	5.01e-06	8.24e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—ocular cancer	4.98e-06	8.19e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—ocular cancer	4.82e-06	7.94e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—EP300—ocular cancer	4.78e-06	7.86e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—ocular cancer	4.76e-06	7.83e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—ocular cancer	4.7e-06	7.73e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TGFB1—ocular cancer	4.69e-06	7.72e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—ocular cancer	4.69e-06	7.72e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—ocular cancer	4.65e-06	7.66e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—ocular cancer	4.59e-06	7.55e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—ocular cancer	4.49e-06	7.39e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—ocular cancer	4.42e-06	7.28e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—ocular cancer	4.36e-06	7.17e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—ocular cancer	4.27e-06	7.02e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—ocular cancer	4.26e-06	7.01e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—ocular cancer	4.2e-06	6.92e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—ocular cancer	4.17e-06	6.86e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—ocular cancer	3.86e-06	6.35e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—EP300—ocular cancer	3.82e-06	6.28e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—ocular cancer	3.69e-06	6.07e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—ocular cancer	3.68e-06	6.06e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—ocular cancer	3.26e-06	5.36e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—ocular cancer	3.06e-06	5.03e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—EP300—ocular cancer	3.05e-06	5.01e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—ocular cancer	2.89e-06	4.75e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—EP300—ocular cancer	2.35e-06	3.87e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—ocular cancer	2.31e-06	3.79e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—ocular cancer	1.84e-06	3.03e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—ocular cancer	1.42e-06	2.34e-06	CbGpPWpGaD
